EpiBiologics, a preclinical stage company advancing new bispecific antibody therapeutics for extracellular protein degradation, is presenting data today on its EpiTAC protein degraders in oncology demonstrating robust in vivo anti-tumor activity and survival benefit. EpiTAC bispecific antibodies leverage cell-surface degrader receptors enriched in disease tissue to selectively degrade membrane and extracellular targets and address significant unmet needs.
"We believe EpiTACs are a promising new modality, especially for difficult-to-drug targets,” said Ann Lee-Karlon, Ph.D., President and CEO of EpiBiologics. "We’re committed to advancing EpiTACs for diverse targets in oncology and other disease areas."
Congratulations to everyone at the Wells lab, especially Jim Wells!